Content about Alkermes

March 8, 2012
Bydureon takes on diabetes

The market for drugs to treat diabetes — especially Type 2 diabetes — has shown quite a bit of activity lately.

March 5, 2012
Mark Stejbach joins Alkermes

Alkermes has appointed a new chief commercial officer.

February 13, 2012
Bydureon officially hits market

Amylin Pharmaceuticals and Alkermes announced that their Type 2 diabetes treatment now is available by prescription in U.S. pharmacies.

February 3, 2012
New diabetes drug launches show primary care market still strong

For all the fears about the patent cliff, at least one disease state seems to be on the up-and-up in terms of new drug development and new products.

February 3, 2012
Survey: Endocrinologists would prescribe Bydureon for 20% of patients

Endocrinologists would prescribe a newly approved weekly treatment for Type 2 diabetes to one-fifth of their patients, a new survey showed.

January 30, 2012
FDA approves Bydureon

The Food and Drug Administration has approved a long-acting injected diabetes drug made by Amylin Pharmaceuticals and Alkermes, the two companies said.

November 8, 2011
Lilly, Amylin terminate diabetes alliance

Eli Lilly and Amylin Pharmaceuticals are ending their diabetes-drug alliance, the two companies said Tuesday.

October 14, 2011
DPP-IV inhibitors, GLP-1 analogues to see strongest growth among Type 2 diabetes drugs through 2020, study finds

Two classes of drugs for treating Type 2 diabetes will experience the biggest growth in market share of all classes of drugs for the condition, according to a new study by Decision Resources.

October 11, 2011
New drugs offer hope for better diabetes treatment

The recent film “Contagion” depicts the world descending to chaos due to the spread of an extremely deadly virus. But in reality, one of the most serious epidemics doesn’t come from an infectious agent but from people’s life choices.


September 12, 2011
Studies: Bydureon shows improvements in cardiovascular health

Patients treated with a long-acting drug for Type 2 diabetes experienced a reduction in cardiovascular health risk factors, according to results of a study presented at the European Association for the Study of Diabetes' annual meeting.

August 11, 2011
FDA sets review date for Bydureon

The Food and Drug Administration has acknowledged the resubmission of an investigational Type 2 diabetes drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes.

July 28, 2011
Bydureon reply submitted to FDA

Drug makers Eli Lilly, Amylin Pharmaceuticals and Alkermes are giving their long-acting form of an injected drug for Type 2 diabetes another try at the Food and Drug Administration.

July 6, 2011
Exenatide improves glucose control among diabetes patients in mid-stage trial

A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.

June 20, 2011
Lilly, BI gear up to present data from studies of diabetes drugs

Just after the approval of their new treatment for Type 2 diabetes, Eli Lilly and Boehringer Ingelheim plan to present data in more than two dozen presentations at the American Diabetes Association Scientific Sessions starting this week.

June 9, 2011
Court vacates Amylin restraining order against Eli Lilly

A federal court has ruled in favor of drug maker Eli Lilly & Co. in a dispute with Amylin Pharmaceuticals over Lilly’s partnership with German drug maker Boehringer Ingelheim.

May 10, 2011
Alkermes to buy Elan Drug Technologies

Alkermes will buy Irish drug maker Elan’s drug formulation and manufacturing business for $960 million, the two companies said Monday.

October 19, 2010
FDA declines to approve Bydureon

The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli...

June 20, 2010
Roche implements risk-mitigation plan for taspoglutide

Swiss drug maker Roche has started a risk-mitigation plan in the late-stage clinical trial of...

March 14, 2010
FDA demands REMS for Bydureon

Drug makers Eli Lilly, Amylin Pharmaceuticals and Alkermes encountered a speed bump in their efforts...

February 16, 2010
Novo Nordisk announces new once-daily treatment for Type 2 diabetes

A new injectable Novo Nordisk drug for diabetes is on the shelves, the Danish drug...

February 10, 2010
Roche to expand diabetes pipeline

Diabetes patients may soon find themselves with an expanded range of treatment options....

January 25, 2010
Decision Resources projects proprietary clinical gold standard status for Byetta

WALTHAM, Mass. A once-weekly treatment for Type 2 diabetes will likely become a popular treatment...

© 2013 Drug Store News. All Rights Reserved.